Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Hydra Biosciences grosses $18.9mm with financing

Executive Summary

Hydra Biosciences (molecular regeneration medicines) has raised $18.9mm with its Series B private placement of shares. Lead investor Lilly BioVentures was joined by new backer BioVentures Investors and returning participants Polaris Venture Partners, Abingworth, New Enterprise Associates, Advanced Technology Ventures, and Boston Medical Investors. Abbott Laboratories also participated as part of its 2002 proliferative vascular disease agreement with Hydra Biosciences.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Gene Therapy, Cell Therapy
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies